texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials



Mika Cline, M.D.

General Summary

Prior to joining Texas Oncology Dr. Cline worked at the Cleveland Clinic in the area of gastrointestinal cancers in addition to having worked with The US Oncology Network in Nevada.


July 1999-June 2002: Fellowship in Hematology/Oncology, University of Kentucky, Lexington Kentucky June 1996- June 1999: Internship and Residency in Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa August 1992-May 1996 M.D., University of Louisville, Louisville Kentucky August 1987-May 1991 B.A., University of Louisville, Louisville Kentucky Major: Biology

Medical Practice

Other Information

Dr. Cline enjoys spending time with her family, reading, baking and outdoor activities. Every fall, she treats her family and friends to homemade apple pies and pear butter from her family’s fruit trees.

Accolades & Memberships

American Society of Clinical Oncologists, American Medical Association, Southwest Oncology Group.

Community Service

Research Interest

She has a special interest in cancers of the gastrointestinal tract as well as clinical research within oncology. She also participates in and advocates for clinical cancer research within community oncology practices.



  • Brentuximab Vedotin in combination with Dacarbazine or Bendamustine for frontline Treatment of Hodgkin Lymphoma in patients aged 60 years and above: interim results of a multicohort phase II study.

    57th Annual ASH Annual Meeting, 2015

  • A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

    Annals of Oncology, 2015

  • SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

    ASCO University, 2013

  • Paclitaxel, gemcitabine, irradiation, and R115777 for pancreas cancer

    OncoTargets and Therapy, 2013